The cholinergic antagonist gymnodimine improves aβ and tau neuropathology in an in vitro model of alzheimer disease

Cellular Physiology and Biochemistry

Volumn 27, Issue 6, 2011, Pages 783-794

  Alonso, Eva ^a   Vale, Carmen ^a   Vieytes, Mercedes R ^a   Laferla, Frank M ^b   Giménez Llort, Lydia ^c   Botana, Luis M ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

Acetylcholine; Alzheimer disease; Beta amyloid; Gymnodimine; Tau protein

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; GYMNODIMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL PRODUCT; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; DRUG MECHANISM; IN VITRO SELECTION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

DINOPHYCEAE; KARENIA SELLIFORMIS;

EID: 79959463136     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000330086     Document Type: Article

References (56)

1. Miles CO, Wilkins AL, Stirling DJ, MacKenzie AL: Gymnodimine c, an isomer of gymnodimine b, from karenia selliformis. J Agric Food Chem 2003;51:4838-4840.
2. Munday R, Towers NR, Mackenzie L, Beuzenberg V, Holland PT, Miles CO: Acute toxicity of gymnodimine to mice. Toxicon 2004;44:173-178. (Pubitemid 38891547)
3. Kharrat R, Servent D, Girard E, Ouanounou G, Amar M, Marrouchi R, Benoit E, Molgo J: The marine phycotoxin gymnodimine targets muscular and neuronal nicotinic acetylcholine receptor subtypes with high affinity. J Neurochem 2008;107:952-963.
4. Bourne Y, Radic Z, Araoz R, Talley TT, Benoit E, Servent D, Taylor P, Molgo J, Marchot P: Structural determinants in phycotoxins and achbp conferring high affinity binding and nicotinic achr antagonism. Proc Natl Acad Sci USA 2010;107:6076-6081.
5. Selkoe DJ: Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001;3:75-80.
6. Honig LS, Mayeux R: Natural history of alzheimer's disease. Aging (Milano) 2001;13:171-182. (Pubitemid 32600084)
7. Buckingham SD, Jones AK, Brown LA, Sattelle DB: Nicotinic acetylcholine receptor signalling: Roles in alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 2009;61:39-61.
8. Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
9. Francis PT, Palmer AM, Snape M, Wilcock GK: The cholinergic hypothesis of alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147. (Pubitemid 29103513)
10. Arneric SP, Holladay M, Williams M: Neuronal nicotinic receptors: A perspective on two decades of drug discovery research. Biochem Pharmacol 2007;74:1092-1101. (Pubitemid 47417924)
11. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A: Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 1998;792:331-334. (Pubitemid 28267549)
12. Deng J, Shen C, Wang YJ, Zhang M, Li J, Xu ZQ, Gao CY, Fang CQ, Zhou HD: Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats. Eur J Pharmacol 2010;637:83-88.
13. Martin SE, de Fiebre NE, de Fiebre CM: The alpha7 nicotinic acetylcholine receptor-selective antagonist, methyllycaconitine, partially protects against beta-amyloid1-42 toxicity in primary neuron-enriched cultures. Brain Res 2004;1022:254-256. (Pubitemid 39195008)
14. Vale C, Alonso E, Rubiolo JA, Vieytes MR, LaFerla FM, Gimenez-Llort L, Botana LM: Profile for amyloid-beta and tau expression in primary cortical cultures from 3xtg-ad mice. Cell Mol Neurobiol 2010;30:577-590.
15. Vale C, Nicolaou KC, Frederick MO, Gomez-Limia B, Alfonso A, Vieytes MR, Botana LM: Effects of azaspiracid-1, a potent cytotoxic agent, on primary neuronal cultures. A structure-activity relationship study. J Med Chem 2007;50:356-363. (Pubitemid 46147715)
16. Varming T, Drejer J, Frandsen A, Schousboe A: Characterization of a chemical anoxia model in cerebellar granule neurons using sodium azide: Protection by nifedipine and mk-801. J Neurosci Res 1996;44:40-46. (Pubitemid 26108848)
17. Grynkiewicz G, Poenie M, Tsien RY: A new generation of ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450. (Pubitemid 15114340)
18. Koh JY, Yang LL, Cotman CW: Betaamyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990;533:315-320. (Pubitemid 20377714)
19. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE: Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-389.
20. Gazulla J, Cavero-Nagore M: [glutamate and alzheimer's disease]. Rev Neurol 2006;42:427-432. (Pubitemid 47372920)
21. Takada-Takatori Y, Kume T, Izumi Y, Ohgi Y, Niidome T, Fujii T, Sugimoto H, Akaike A: Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull 2009;32:318-324.
22. Bano D, Nicotera P: Ca2+ signals and neuronal death in brain ischemia. Stroke 2007;38:674-676. (Pubitemid 46184239)
23. Mattson MP: Calcium and neurodegeneration. Aging Cell 2007;6:337-350.
24. Apelt J, Kumar A, Schliebs R: Impairment of cholinergic neurotransmission in adult and aged transgenic tg2576 mouse brain expressing the swedish mutation of human beta-amyloid precursor protein. Brain Res 2002;953:17-30. (Pubitemid 35217803)
25. Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, Nomikos GG: Cholinergic dysfunction in a mouse model of alzheimer disease is reversed by an anti-a beta antibody. J Clin Invest 2006;116:825-832. (Pubitemid 43326892)
26. Pakaski M, Kalman J: Interactions between the amyloid and cholinergic mechanisms in alzheimer's disease. Neurochem Int 2008;53:103-111.
27. Langmead CJ, Watson J, Reavill C: Muscarinic acetylcholine receptors as cns drug targets. Pharmacol Ther 2008;117:232-243.
28. Birks J: Cholinesterase inhibitors for alzheimer's disease. Cochrane Database Syst Rev 2006:CD005593.
29. Rouse ST, Gilmor ML, Levey AI: Differential presynaptic and postsynaptic expression of m1-m4 muscarinic acetylcholine receptors at the perforant pathway/granule cell synapse. Neuroscience 1998;86:221-232. (Pubitemid 28270868)
30. Weber JT, Rzigalinski BA, Ellis EF: Calcium responses to caffeine and muscarinic receptor agonists are altered in traumatically injured neurons. J Neurotrauma 2002;19:1433-1443. (Pubitemid 35403672)
31. Ladner CJ, Lee JM: Reduced high-affinity agonist binding at the m(1) muscarinic receptor in alzheimer's disease brain: Differential sensitivity to agonists and divalent cations. Exp Neurol 1999;158:451-458. (Pubitemid 29382836)
32. Lai MK, Lai OF, Keene J, Esiri MM, Francis PT, Hope T, Chen CP: Psychosis of alzheimer's disease is associated with elevated muscarinic m2 binding in the cortex. Neurology 2001;57:805-811. (Pubitemid 32845499)
33. Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM, Hope T, Chen CP, Wong PT: Impaired coupling of muscarinic m1 receptors to g-proteins in the neocortex is associated with severity of dementia in alzheimer's disease. Neurobiol Aging 2006;27:1216-1223. (Pubitemid 44088578)
34. Billard W, Binch H, Crosby G, McQuade RD: Identification of the primary muscarinic autoreceptor subtype in rat striatum as m2 through a correlation of in vivo microdialysis and in vitro receptor binding data. J Pharmacol Exp Ther 1995;273:273-279.
35. Mousavi M, Hellstrom-Lindahl E: Nicotinic receptor agonists and antagonists increase sappalpha secretion and decrease abeta levels in vitro. Neurochem Int 2009;54:237-244.
36. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM: M1 receptors play a central role in modulating ad-like pathology in transgenic mice. Neuron 2006;49:671-682. (Pubitemid 43290127)
37. Zamani MR, Allen YS, Owen GP, Gray JA: Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35)) in hippocampal cultures. Neuroreport 1997;8:513-517. (Pubitemid 27180112)
38. Porzig R, Singer D, Hoffmann R: Epitope mapping of mabs at8 and tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun 2007;358:644-649. (Pubitemid 46755753)
39. Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, Martin JJ, Gheuens J: Monoclonal antibodies with selective specificity for alzheimer tau are directed against phosphatasesensitive epitopes. Acta Neuropathol 1992;84:265-272.
40. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J: Current advances on different kinases involved in tau phosphorylation, and implications in alzheimer's disease and tauopathies. Curr Alzheimer Res 2005;2:3-18. (Pubitemid 41389255)
41. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF: Distribution of active glycogen synthase kinase 3beta (gsk-3beta) in brains staged for alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999;58:1010-1019. (Pubitemid 29441929)
42. Sul D, Kim HS, Lee D, Joo SS, Hwang KW, Park SY: Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci 2009;84:257-262.
43. Bell KA, O'Riordan KJ, Sweatt JD, Dineley KT: Mapk recruitment by betaamyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J Neurochem 2004;91:349-361. (Pubitemid 39363434)
44. Wang HY, Li W, Benedetti NJ, Lee DH: Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 2003;278:31547-31553. (Pubitemid 37048332)
45. Fonfria ES, Vilarino N, Espina B, Louzao MC, Alvarez M, Molgo J, Araoz R, Botana LM: Feasibility of gymnodimine and 13-desmethyl c spirolide detection by fluorescence polarization using a receptor-based assay in shellfish matrixes. Anal Chim Acta 2010;657:75-82.
46. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P: Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, s 24795, normalizes alpha 7 nicotinic acetylcholine and nmda receptor function in alzheimer's disease brain. J Neurosci 2009;29:10961-10973.
47. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB: Betaamyloid( 1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for alzheimer's disease pathology. J Biol Chem 2000;275:5626-5632. (Pubitemid 30115201)
48. Wang HY, Lee DH, Davis CB, Shank RP: Amyloid peptide abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 2000;75:1155-1161. (Pubitemid 30660505)
49. Hu M, Waring JF, Gopalakrishnan M, Li J: Role of gsk-3beta activation and alpha7 nachrs in abeta(1-42)-induced tau phosphorylation in pc12 cells. J Neurochem 2008;106:1371-1377.
50. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD: Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to alzheimer's disease. J Neurosci 2001;21:4125-4133. (Pubitemid 32538537)
51. Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S: Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 2002;115:201-211. (Pubitemid 35232701)
52. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M: In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist abt-107: Preclinical considerations in alzheimer's disease. J Pharmacol Exp Ther 2010;334:875-886.
53. Haydar SN, Dunlop J: Neuronal nicotinic acetylcholine receptors -targets for the development of drugs to treat cognitive impairment associated with schizophrenia and alzheimer's disease. Curr Top Med Chem 2010;10:144-152.
54. Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, La Rosa S, Micco I, Pollastrini M, Quinn J, Roncarati R, Scali C, Valacchi M, Varrone M, Zanaletti R: Sar and biological evaluation of sen12333/way-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorg Med Chem 2009;17:5247-5258.
55. Woodruff-Pak DS, Gould TJ: Neuronal nicotinic acetylcholine receptors: Involvement in alzheimer's disease and schizophrenia. Behav Cogn Neurosci Rev 2002;1:5-20.
56. Hogg RC, Bertrand D: Nicotinic acetylcholine receptors as drug targets. Curr Drug Targets CNS Neurol Disord 2004;3:123-130. (Pubitemid 38854907)